2025 Q4 -tulosraportti
41 päivää sitten
‧48 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 105 | - | - | ||
| 456 | - | - | ||
| 82 | - | - | ||
| 874 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·15 t sittenFrom tekinvestor where PHO has answered questions: «Received feedback from PHO regarding reclasification; Please keep in mind that this ruling relates to reclassification based on the Karl Storz Citizen Petition and does not preclude future approvals of scopes by other manufacturers. The FDA’s feedback provides important information and guardrails we did not have before, helping us evaluate more efficient regulatory paths, including data requirements and timelines. We will aim to provide market updates on alternative paths with our partners as soon as possible. Please keep in mind that we are only able to disclose what our partners are willing to communicate about the status of their regulatory strategies and progress. We continue to work with partners on appropriate updates.»
20 t sitten20 t sittenSelv DNB beholder kursmålet etter USA «nyheten»: On Friday 27 March, the US Food and Drug Administration (FDA) denied a petition from Karl Storz, dated 21 October 2022, requesting the FDA reclassify diagnostic endoscopic light source systems (product code OAY) from Class III to Class II. Specifically, the petition asked the FDA to (i) reclassify these devices, (ii) establish appropriate special controls and guidance to ensure safety and effectiveness under a 510(k) pathway, and (iii) take any additional actions necessary to implement the reclassification. While a reclassification would have been positive for Photocure, potentially enabling a next level of growth for Cysview, the current classification does not preclude a future change and the decision does not limit access to the US market. In its response, the FDA outlined the key requirements for reclassification, including additional clinical data and stronger special controls to demonstrate safety and effectiveness under a Class II framework. Importantly, no concerns were raised about the underlying technology. Photocure said it continues to actively support multiple device manufacturers pursuing established alternative regulatory pathways. We would view a modestly negative share price reaction as fair. While we had not factored in a down classification in our estimates (leaving a positive outcome as upside potential), we believe there has been some market speculation regarding a positive outcome. This potentially significant catalyst for the case is now removed – at least in the short run. Overall, we view the investment case as intact. Estimates, recommendation and target price are unchanged and as of the most recently published report PhotoCure BUY Price NOK 63.7 Target NOK 75 PHO.OL PHO NO Healthcare Next report: 7 May -26 Best regards Geir Hiller Holom Financial Analyst DNB Bank ASA, DNB Carnegie
·8 t sittenNot worried about what the FDA is doing. They are no longer the locomotive in the world. What drug authorities in China and what EMEA are doing is more important. The USA will put spokes in the wheels for China and Europe. They will not get anywhere. They will probably come crawling eventually when treatment results come and Cevira is rolled out.
·1 päivä sittenSo the shareholders have received clarification on two of the surest, and most price-driving triggers. Those that were supposed to take the price up to several hundred kroner. All according to the very most skilled writers in here. The intelligence itself, and those who truly understand pho. I myself think it went so-so. And barely even that.·17 t sittenContinued growth in US sales. And Cevira was approved for sale in the market. In that respect, very good. How many biotechs manage to bring a final product to markets. Cevira's patient group is large and there is an unmet need. Then it's great with the achievement of Asieris and Photocure.
·1 päivä sitten🐷 what's up 🐷- ·1 päivä sittenAladin you forgot this one from the analysis from ABG. An updated request or alternative regulatory paths, which the company has referred to on several occasions, can still over time contribute to realizing the bull case
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
41 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 t sittenFrom tekinvestor where PHO has answered questions: «Received feedback from PHO regarding reclasification; Please keep in mind that this ruling relates to reclassification based on the Karl Storz Citizen Petition and does not preclude future approvals of scopes by other manufacturers. The FDA’s feedback provides important information and guardrails we did not have before, helping us evaluate more efficient regulatory paths, including data requirements and timelines. We will aim to provide market updates on alternative paths with our partners as soon as possible. Please keep in mind that we are only able to disclose what our partners are willing to communicate about the status of their regulatory strategies and progress. We continue to work with partners on appropriate updates.»
- 20 t sitten20 t sittenSelv DNB beholder kursmålet etter USA «nyheten»: On Friday 27 March, the US Food and Drug Administration (FDA) denied a petition from Karl Storz, dated 21 October 2022, requesting the FDA reclassify diagnostic endoscopic light source systems (product code OAY) from Class III to Class II. Specifically, the petition asked the FDA to (i) reclassify these devices, (ii) establish appropriate special controls and guidance to ensure safety and effectiveness under a 510(k) pathway, and (iii) take any additional actions necessary to implement the reclassification. While a reclassification would have been positive for Photocure, potentially enabling a next level of growth for Cysview, the current classification does not preclude a future change and the decision does not limit access to the US market. In its response, the FDA outlined the key requirements for reclassification, including additional clinical data and stronger special controls to demonstrate safety and effectiveness under a Class II framework. Importantly, no concerns were raised about the underlying technology. Photocure said it continues to actively support multiple device manufacturers pursuing established alternative regulatory pathways. We would view a modestly negative share price reaction as fair. While we had not factored in a down classification in our estimates (leaving a positive outcome as upside potential), we believe there has been some market speculation regarding a positive outcome. This potentially significant catalyst for the case is now removed – at least in the short run. Overall, we view the investment case as intact. Estimates, recommendation and target price are unchanged and as of the most recently published report PhotoCure BUY Price NOK 63.7 Target NOK 75 PHO.OL PHO NO Healthcare Next report: 7 May -26 Best regards Geir Hiller Holom Financial Analyst DNB Bank ASA, DNB Carnegie·8 t sittenNot worried about what the FDA is doing. They are no longer the locomotive in the world. What drug authorities in China and what EMEA are doing is more important. The USA will put spokes in the wheels for China and Europe. They will not get anywhere. They will probably come crawling eventually when treatment results come and Cevira is rolled out.
- ·1 päivä sittenSo the shareholders have received clarification on two of the surest, and most price-driving triggers. Those that were supposed to take the price up to several hundred kroner. All according to the very most skilled writers in here. The intelligence itself, and those who truly understand pho. I myself think it went so-so. And barely even that.·17 t sittenContinued growth in US sales. And Cevira was approved for sale in the market. In that respect, very good. How many biotechs manage to bring a final product to markets. Cevira's patient group is large and there is an unmet need. Then it's great with the achievement of Asieris and Photocure.
- ·1 päivä sitten🐷 what's up 🐷
- ·1 päivä sittenAladin you forgot this one from the analysis from ABG. An updated request or alternative regulatory paths, which the company has referred to on several occasions, can still over time contribute to realizing the bull case
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 105 | - | - | ||
| 456 | - | - | ||
| 82 | - | - | ||
| 874 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
2025 Q4 -tulosraportti
41 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 t sittenFrom tekinvestor where PHO has answered questions: «Received feedback from PHO regarding reclasification; Please keep in mind that this ruling relates to reclassification based on the Karl Storz Citizen Petition and does not preclude future approvals of scopes by other manufacturers. The FDA’s feedback provides important information and guardrails we did not have before, helping us evaluate more efficient regulatory paths, including data requirements and timelines. We will aim to provide market updates on alternative paths with our partners as soon as possible. Please keep in mind that we are only able to disclose what our partners are willing to communicate about the status of their regulatory strategies and progress. We continue to work with partners on appropriate updates.»
- 20 t sitten20 t sittenSelv DNB beholder kursmålet etter USA «nyheten»: On Friday 27 March, the US Food and Drug Administration (FDA) denied a petition from Karl Storz, dated 21 October 2022, requesting the FDA reclassify diagnostic endoscopic light source systems (product code OAY) from Class III to Class II. Specifically, the petition asked the FDA to (i) reclassify these devices, (ii) establish appropriate special controls and guidance to ensure safety and effectiveness under a 510(k) pathway, and (iii) take any additional actions necessary to implement the reclassification. While a reclassification would have been positive for Photocure, potentially enabling a next level of growth for Cysview, the current classification does not preclude a future change and the decision does not limit access to the US market. In its response, the FDA outlined the key requirements for reclassification, including additional clinical data and stronger special controls to demonstrate safety and effectiveness under a Class II framework. Importantly, no concerns were raised about the underlying technology. Photocure said it continues to actively support multiple device manufacturers pursuing established alternative regulatory pathways. We would view a modestly negative share price reaction as fair. While we had not factored in a down classification in our estimates (leaving a positive outcome as upside potential), we believe there has been some market speculation regarding a positive outcome. This potentially significant catalyst for the case is now removed – at least in the short run. Overall, we view the investment case as intact. Estimates, recommendation and target price are unchanged and as of the most recently published report PhotoCure BUY Price NOK 63.7 Target NOK 75 PHO.OL PHO NO Healthcare Next report: 7 May -26 Best regards Geir Hiller Holom Financial Analyst DNB Bank ASA, DNB Carnegie·8 t sittenNot worried about what the FDA is doing. They are no longer the locomotive in the world. What drug authorities in China and what EMEA are doing is more important. The USA will put spokes in the wheels for China and Europe. They will not get anywhere. They will probably come crawling eventually when treatment results come and Cevira is rolled out.
- ·1 päivä sittenSo the shareholders have received clarification on two of the surest, and most price-driving triggers. Those that were supposed to take the price up to several hundred kroner. All according to the very most skilled writers in here. The intelligence itself, and those who truly understand pho. I myself think it went so-so. And barely even that.·17 t sittenContinued growth in US sales. And Cevira was approved for sale in the market. In that respect, very good. How many biotechs manage to bring a final product to markets. Cevira's patient group is large and there is an unmet need. Then it's great with the achievement of Asieris and Photocure.
- ·1 päivä sitten🐷 what's up 🐷
- ·1 päivä sittenAladin you forgot this one from the analysis from ABG. An updated request or alternative regulatory paths, which the company has referred to on several occasions, can still over time contribute to realizing the bull case
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 105 | - | - | ||
| 456 | - | - | ||
| 82 | - | - | ||
| 874 | - | - |
Välittäjätilasto
Dataa ei löytynyt